শুধুমাত্র তথ্যমূলক — চিকিৎসা পরামর্শ নয়। সর্বদা লাইসেন্সপ্রাপ্ত স্বাস্থ্যসেবা প্রদানকারীর পরামর্শ নিন।

MedBD
EN
Community data Updated 2 মাস আগে

ইঙ্গিত

K-One MM (Vitamin K-1) is indicated for the following conditions: prophylaxis and treatment of haemorrhagic disease in the newborn; haemorrhage or risk of haemorrhage resulting from severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various causes, including overdosage of coumarin-type anticoagulants, their use in combination with phenylbutazone, and other forms of vitamin K deficiency (e.g. in obstructive jaundice, liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates); and prevention and treatment of bleeding due to vitamin K deficiency.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Phytomenadione acts as a procoagulant factor. It forms part of a liver-based carboxylase system and is required for the post-translational carboxylation of clotting factors II (prothrombin), VII, IX and X, as well as the clotting inhibitors protein C and protein S. It is not effective in hereditary hypoprothrombinemia or in hypoprothrombinemia caused by severe liver failure. A deficiency of this vitamin increases the risk of haemorrhagic disease of the newborn. By promoting the liver's synthesis of the coagulation factors mentioned above, administering Phytomenadione can correct abnormal clotting and stop bleeding caused by its deficiency.

Pregnancy & Breastfeeding

Not relevant.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Prophylaxis for mild hemorrhage or a tendency toward hemorrhage: in neonates, the usual dose is 2 mg given orally at birth or shortly afterward, followed by a further 2 mg on the 4th to 5th day and another 2 mg on the 28th to 30th day. If the oral route is not suitable, 2 mg may instead be given by IM or IV injection. Children over 1 year of age may be given 5 to 10 mg orally. For children who cannot be relied upon to receive a second oral dose, or breastfed children who cannot be relied upon to receive a third oral dose, a single 1 mg (0.1 ml) dose given by IM injection is recommended. Therapy: an initial dose of 1 mg is given by intravenous injection, with further doses given as needed depending on the clinical picture and coagulation status. Neonates with special risk factors, such as prematurity, birth asphyxia (inadequate oxygen intake during birth), obstructive jaundice, inability to swallow, or maternal use of anticoagulants or anti-epileptics, should receive 1 mg by IM or IV injection at birth or shortly afterward if the oral route is not suitable. In premature infants weighing less than 2.5 kg, IM and IV doses should not exceed 0.4 mg/kg, and the size and frequency of any further doses should be guided by coagulation status. To ensure newborns receive full protection, 3 prophylactic doses of vitamin K should be given orally according to the schedule above.